CA2295199A1 - Method for treating vascular proliferative diseases with p27 and fusions thereof - Google Patents

Method for treating vascular proliferative diseases with p27 and fusions thereof Download PDF

Info

Publication number
CA2295199A1
CA2295199A1 CA002295199A CA2295199A CA2295199A1 CA 2295199 A1 CA2295199 A1 CA 2295199A1 CA 002295199 A CA002295199 A CA 002295199A CA 2295199 A CA2295199 A CA 2295199A CA 2295199 A1 CA2295199 A1 CA 2295199A1
Authority
CA
Canada
Prior art keywords
fusions
proliferative diseases
vascular proliferative
treating vascular
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002295199A
Other languages
French (fr)
Other versions
CA2295199C (en
Inventor
Gary J. Nabel
Elizabeth G. Nabel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
The Regents Of The University Of Michigan
Gary J. Nabel
Elizabeth G. Nabel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan, Gary J. Nabel, Elizabeth G. Nabel filed Critical The Regents Of The University Of Michigan
Publication of CA2295199A1 publication Critical patent/CA2295199A1/en
Application granted granted Critical
Publication of CA2295199C publication Critical patent/CA2295199C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention is directed to a method of vascular proliferative disease by administering in vivo a gene encoding p27.
CA002295199A 1997-07-21 1998-07-21 Method for treating vascular proliferative diseases with p27 and fusions thereof Expired - Fee Related CA2295199C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/897,333 1997-07-21
US08/897,333 US6177272B1 (en) 1997-07-21 1997-07-21 Method for treating vascular proliferative diseases with p27 and fusions thereof
PCT/US1998/015025 WO1999003508A2 (en) 1997-07-21 1998-07-21 METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF

Publications (2)

Publication Number Publication Date
CA2295199A1 true CA2295199A1 (en) 1999-01-28
CA2295199C CA2295199C (en) 2007-07-03

Family

ID=25407780

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295199A Expired - Fee Related CA2295199C (en) 1997-07-21 1998-07-21 Method for treating vascular proliferative diseases with p27 and fusions thereof

Country Status (8)

Country Link
US (2) US6177272B1 (en)
EP (1) EP0998307B1 (en)
JP (1) JP2001510028A (en)
AT (1) ATE342067T1 (en)
AU (1) AU8502198A (en)
CA (1) CA2295199C (en)
DE (1) DE69836139T2 (en)
WO (1) WO1999003508A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413943B1 (en) 1999-03-01 2002-07-02 Cell Genesys, Inc. Methods and reagents for inhibiting proliferation of smooth muscle cells
US6521602B1 (en) 1999-03-01 2003-02-18 Gpc Biotech Inc. Anti-neoplastic compositions and uses thereof
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
WO2001021793A1 (en) 1999-09-22 2001-03-29 Nobuyuki Miyasaka p21Cip1 REMEDIES FOR RHEUMATISM
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
DE60124285T3 (en) * 2000-09-29 2011-03-17 Cordis Corp., Miami Lakes COATED MEDICAL EQUIPMENT
US20020098998A1 (en) * 2001-01-22 2002-07-25 Marks Andrew R. P27 prevents cellular migration
US20030013638A1 (en) * 2001-01-22 2003-01-16 Marks Andrew R. P27 prevents cellular migration
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US20030065345A1 (en) * 2001-09-28 2003-04-03 Kevin Weadock Anastomosis devices and methods for treating anastomotic sites
US20050069918A1 (en) 2003-05-29 2005-03-31 Francois Claret JAB1 as a prognostic marker and a therapeutic target for human cancer
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
CA2715765A1 (en) * 2008-02-19 2009-08-27 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
CN114401992A (en) 2019-07-05 2022-04-26 艾欧麦克斯治疗股份公司 Antibodies to IGSF11(VSIG3) that bind IGC2 and uses thereof
US20240010720A1 (en) 2020-07-06 2024-01-11 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5688665A (en) * 1994-01-07 1997-11-18 Fred Hutchinson Cancer Research Center Isolated nucleic acid molecules encoding the p27 KIP-1 protein
US6242575B1 (en) 1994-01-07 2001-06-05 Fred Hutchinson Institute For Cancer Research Antibodies for detecting p27 protein
US6316208B1 (en) 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US6355774B1 (en) 1994-01-07 2002-03-12 Fred Hutchinson Cancer Research Center Isolated p27 protein
US6635450B1 (en) 1994-07-15 2003-10-21 Fred Hutchinson Institute For Cancer Research Isolated P27 protein, nucleic acid molecules encoding same, methods of identifying agents acting on same, and uses of said agents
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US6541197B2 (en) * 1996-01-22 2003-04-01 Human Gene Therapy Research Institute Vehicles for stable transfer of green fluorescent protein gene and methods of use for same
US5672508A (en) * 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
US6110744A (en) * 1996-11-13 2000-08-29 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement

Also Published As

Publication number Publication date
ATE342067T1 (en) 2006-11-15
EP0998307A2 (en) 2000-05-10
CA2295199C (en) 2007-07-03
WO1999003508A2 (en) 1999-01-28
DE69836139T2 (en) 2007-08-16
AU8502198A (en) 1999-02-10
JP2001510028A (en) 2001-07-31
US6177272B1 (en) 2001-01-23
WO1999003508A9 (en) 1999-05-14
US6884431B1 (en) 2005-04-26
DE69836139D1 (en) 2006-11-23
WO1999003508A3 (en) 1999-04-08
EP0998307B1 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
CA2295199A1 (en) Method for treating vascular proliferative diseases with p27 and fusions thereof
EP0690673A4 (en) Systemic gene treatment of connective tissue diseases
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
AU2639695A (en) Novel uses of triplex forming oligonucleotides for the treatment of human diseases
ZA943464B (en) Vascular endothelial growth factor 2
AU674894C (en) Treatment of conditions and disease
HUP9801639A3 (en) Genetic sequences and proteins related to alzheimer's disease, and uses therefor
AU4528493A (en) In vivo gene therapy with intron-free sequence of interest
CA2064689A1 (en) Stabilized protein or peptide conjugates
WO1996034953A3 (en) Cd16-ii variants
AU1916995A (en) 4-amino derivatives of mycophenolic acid with immunosuppressant activity
ZA943465B (en) Transforming growth factor alpha H1
NO904378L (en) PROCEDURE FOR THE PREPARATION OF A MODIFIED PROTEIN FOR THERAPEUTIC USE.
ZA931174B (en) Treatment of disease employing hyaluronic acid and nsaids.
WO1996019580A3 (en) Telomerase protein component
AU4759390A (en) Method of medical treatment of alzheimer's disease
OA09362A (en) "Production and use of porphyrins".
AU6459596A (en) Methods of treatment of neurological diseases by interferon antagonists
DE69007065T2 (en) Use of diadenosine 5 ', 5' '' - p1, p4-tetraphosphate for the manufacture of a medicament for the treatment of heart diseases.
EP0988316A4 (en) Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
HUP0000785A3 (en) Ointment for the treatment of burns and other skin diseases
CZ194795A3 (en) Derivatives of pyrazolylacrylic acid, process of their preparation and intermediates therefor, microbicides containing such acids and their use
AU6406098A (en) Use of minalcipran and its derivatives for preparing a medicine for treating certain psychiatric diseases
ZA924128B (en) New combination preparations for treatment of Parkinson's disease.
HUP0004647A3 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed